Literature DB >> 14999720

High-throughput determination of the free fraction of drugs strongly bound to plasma proteins.

Joachim Schuhmacher1, Christian Kohlsdorfer, Klaus Bühner, Tim Brandenburger, Renate Kruk.   

Abstract

Quantification of protein binding of new chemical entities is an important early screening step during drug discovery and is of fundamental interest for the estimation of safety margins during drug development. In this publication, we describe the development of a new high-throughput assay for the determination of the free drug fraction in plasma (fu). The new technique is an enhancement of the previously published erythrocytes partition method. It is based on the distribution of drugs between plasma water, plasma proteins, and solid-supported lipid membranes (Transil). The execution of protein binding studies by partitioning is dramatically simplified by substituting erythrocytes with commercially available Transil beads, and makes the method particularly suitable for high-throughput studies. Eight Bayer compounds from different compound classes covering a wide range of lipophilicities (log P = 1.9-5.6) and fu values (0.018-35%) were selected for validation of the assay. The results obtained by the new method and by either the erythrocytes partitioning technique or more conventional methods (ultrafiltration and equilibrium dialysis) are identical, confirming that the new method produces valid results even for drugs that are strongly bound to plasma proteins. Precision and accuracy of the data in the cases of very low and high fu values are comparable, indicating that the method is especially suited for highly lipophilic drugs that tend to adsorb to surfaces compared with other methods, like ultrafiltration or equilibrium dialysis, that may produce biased data. The method is also useful for the determination of binding parameters and the pH dependence of fu. In summary, this assay is well suited for high-throughput determination of protein binding during drug discovery and for extended protein binding studies during drug development. Copyright 2004 Wiley-Liss, Inc. and the American Pharmacists Association.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14999720     DOI: 10.1002/jps.10588

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  11 in total

1.  Determination of drug binding to plasma proteins using competitive equilibrium binding to dextran-coated charcoal.

Authors:  Leonid M Berezhkovskiy
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-07-14       Impact factor: 2.745

2.  Irreversible binding of an anticancer compound (BI-94) to plasma proteins.

Authors:  Nagsen Gautam; Rhishikesh Thakare; Sandeep Rana; Amarnath Natarajan; Yazen Alnouti
Journal:  Xenobiotica       Date:  2015-04-14       Impact factor: 1.908

3.  Pharmacokinetics, protein binding and metabolism of a quinoxaline urea analog as an NF-κB inhibitor in mice and rats by LC-MS/MS.

Authors:  Nagsen Gautam; Sai Praneeth R Bathena; Qianyi Chen; Amarnath Natarajan; Yazen Alnouti
Journal:  Biomed Chromatogr       Date:  2013-03-10       Impact factor: 1.902

4.  Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.

Authors:  Antonius A Miller; Daryl J Murry; Kouros Owzar; Donna R Hollis; Erin B Kennedy; Ghassan Abou-Alfa; Apurva Desai; Jimmy Hwang; Miguel A Villalona-Calero; E Claire Dees; Lionel D Lewis; Marwan G Fakih; Martin J Edelman; Fred Millard; Richard C Frank; Raymond J Hohl; Mark J Ratain
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

5.  High-throughput 1,536-well fluorescence polarization assays for α(1)-acid glycoprotein and human serum albumin binding.

Authors:  Adam Yasgar; Silviya D Furdas; David J Maloney; Ajit Jadhav; Manfred Jung; Anton Simeonov
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

6.  Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models.

Authors:  Dieter Zopf; Iduna Fichtner; Ajay Bhargava; Wolfram Steinke; Karl-Heinz Thierauch; Konstanze Diefenbach; Scott Wilhelm; Frank-Thorsten Hafner; Michael Gerisch
Journal:  Cancer Med       Date:  2016-10-13       Impact factor: 4.452

7.  Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies.

Authors:  Carsten Möller; Wilhelm Bone; Arwed Cleve; Ulrich Klar; Andrea Rotgeri; Antje Rottmann; Marcus-Hillert Schultze-Mosgau; Andrea Wagenfeld; Wolfgang Schwede
Journal:  ChemMedChem       Date:  2018-11-06       Impact factor: 3.466

8.  Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study.

Authors:  Niladri Chattopadhyay; Kai Riecke; Sandra Ligges; Torsten Zimmermann; Atef Halabi; Marcus-Hillert Schultze-Mosgau
Journal:  Br J Clin Pharmacol       Date:  2019-07-10       Impact factor: 4.335

9.  Pharmacokinetics and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Participants With Renal Impairment.

Authors:  Marcus-Hillert Schultze-Mosgau; Kenneth C Lasseter; Thomas Marbury; Stephanie Loewen; Kai Riecke
Journal:  J Clin Pharmacol       Date:  2020-03-30       Impact factor: 3.126

10.  Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9).

Authors:  Dipti Athavale; Surbhi Chouhan; Vimal Pandey; Shyamananda Singh Mayengbam; Snahlata Singh; Manoj Kumar Bhat
Journal:  Cancer Metab       Date:  2018-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.